Rigel Pharmaceuticals | RIGL - 負債





負債 変化する 日付
Agenus USD 35.54M 2.34M 2025-03
Amgen USD 54.6B 17M 2025-12
Anika Therapeutics USD 0 0 2025-03
Arrowhead Research USD 312.77M 53.52M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Celldex Therapeutics USD 2.34M 285K 2025-12
Daiichi Sankyo JPY 201.14B 99.81B 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Halozyme Therapeutics USD 2.14B 2.01M 2026-03
Heron Therapeutics USD 149.65M 157K 2024-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
Karyopharm Therapeutics USD 299.23M 35.14M 2025-12
Ligand Pharmaceuticals USD 451.49M 494K 2025-12
MacroGenics USD 37.01M 238K 2025-09
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Pfizer USD 63.73B 231M 2026-03
Regeneron Pharmaceuticals USD 2.71B 300K 2026-03
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
Sangamo BioSciences USD 0 0 2022-06
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Veracyte USD 39.65M 799K 2025-12